ECSP10010029A - HUMAN ANTIBODIES HIGH AFFINITY OF HUMAN NERVE GROWTH FACTOR - Google Patents

HUMAN ANTIBODIES HIGH AFFINITY OF HUMAN NERVE GROWTH FACTOR

Info

Publication number
ECSP10010029A
ECSP10010029A EC2010010029A ECSP10010029A ECSP10010029A EC SP10010029 A ECSP10010029 A EC SP10010029A EC 2010010029 A EC2010010029 A EC 2010010029A EC SP10010029 A ECSP10010029 A EC SP10010029A EC SP10010029 A ECSP10010029 A EC SP10010029A
Authority
EC
Ecuador
Prior art keywords
pain
human
growth factor
antibody
nerve growth
Prior art date
Application number
EC2010010029A
Other languages
Spanish (es)
Inventor
Joel H Martin
Lynn Macdonald
Richard Torres
Marc R Morra
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ECSP10010029A publication Critical patent/ECSP10010029A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un anticuerpo o fragmento de unión a antígeno de un anticuerpo humano que se une específicamente a factor de crecimiento de nervio humano (NGF) con una KD de 5 pM o menos, que no reacciona de forma cruzada con neurotrofina-3 (NT-3, y que se une a NGF humano con una KD aproximadamente de 2 a 10 veces mayor que la correspondiente a la unión del anticuerpo o fragmento con NGF de rata o de ratón. Los anticuerpos son útiles para tratar el dolor, que incluye dolor inflamatorio, dolor de incisión post-operatorio, dolor neuropático, dolor de fractura, dolor de fractura osteoporótica, neuralgia post-herpética, osteoartritis, artritis reumatoide, dolor de cáncer, dolor procedente de quemaduras, dolor de articulación de gota, así como enfermedades tales como el carcinoma hepatocelular, el cáncer de pecho y la cirrosis hepática.An antibody or antigen-binding fragment of a human antibody that specifically binds to human nerve growth factor (NGF) with a KD of 5 pM or less, which does not cross-react with neurotrophin-3 (NT-3, and that binds to human NGF with a KD approximately 2 to 10 times greater than that corresponding to the binding of the antibody or fragment with rat or mouse NGF Antibodies are useful for treating pain, including inflammatory pain, pain of post-operative incision, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, burn pain, gout joint pain, as well as diseases such as carcinoma Hepatocellular, breast cancer and liver cirrhosis.

EC2010010029A 2007-08-10 2010-03-10 HUMAN ANTIBODIES HIGH AFFINITY OF HUMAN NERVE GROWTH FACTOR ECSP10010029A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96422407P 2007-08-10 2007-08-10
US99452607P 2007-09-20 2007-09-20
US6286008P 2008-01-28 2008-01-28
US7925908P 2008-07-09 2008-07-09

Publications (1)

Publication Number Publication Date
ECSP10010029A true ECSP10010029A (en) 2010-04-30

Family

ID=39951432

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010029A ECSP10010029A (en) 2007-08-10 2010-03-10 HUMAN ANTIBODIES HIGH AFFINITY OF HUMAN NERVE GROWTH FACTOR

Country Status (31)

Country Link
US (3) US7988967B2 (en)
EP (2) EP2187964B1 (en)
JP (1) JP5632744B2 (en)
KR (2) KR101709488B1 (en)
CN (1) CN101827609B (en)
AU (1) AU2008287037B2 (en)
BR (1) BRPI0815370B8 (en)
CA (1) CA2695997C (en)
CO (1) CO6261383A2 (en)
CR (1) CR11298A (en)
CY (1) CY1116072T1 (en)
DK (1) DK2187964T3 (en)
DO (1) DOP2010000054A (en)
EC (1) ECSP10010029A (en)
ES (1) ES2517872T3 (en)
HR (1) HRP20141025T1 (en)
IL (1) IL203558A (en)
MA (1) MA31695B1 (en)
ME (2) ME00977B (en)
MX (1) MX2010001395A (en)
MY (2) MY161564A (en)
NI (1) NI201000021A (en)
NZ (1) NZ583200A (en)
PL (1) PL2187964T3 (en)
PT (1) PT2187964E (en)
RS (1) RS53661B1 (en)
RU (1) RU2473564C2 (en)
SI (1) SI2187964T1 (en)
TN (1) TN2010000059A1 (en)
WO (1) WO2009023540A1 (en)
ZA (1) ZA201000725B (en)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US9498530B2 (en) * 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
DK1575517T3 (en) 2002-12-24 2012-05-14 Rinat Neuroscience Corp ANTI-NGF ANTIBODIES AND PROCEDURES FOR USING THE SAME
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ITRM20030601A1 (en) * 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
ITRM20050290A1 (en) * 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
PL2187964T3 (en) 2007-08-10 2015-03-31 Regeneron Pharma High affinity human antibodies to human nerve growth factor
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
SI2331090T1 (en) 2008-09-19 2018-04-30 Pfizer Inc. Stable liquid antibody formulation
SI2350075T1 (en) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituted imidazoš1,2bćpyridazine compounds as trk kinase inhibitors
CN102264736B (en) 2008-10-22 2013-08-14 阵列生物制药公司 Substituted pyrazolo[1,5-a]pyrimidine compounds as TRK kinase inhibitors
AU2016202118B2 (en) * 2009-03-20 2017-10-26 Amgen Inc. Carrier immunoglobulins and uses thereof
ES2514319T3 (en) 2009-05-04 2014-10-28 Abbvie Research B.V. Antibodies against nerve growth factor (NGF) with improved in vivo stability
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
DK3241435T3 (en) 2009-07-08 2021-08-23 Kymab Ltd ANIMAL MODELS AND THERAPEUTIC MOLECULES
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
MY173390A (en) * 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
KR20130031247A (en) * 2010-03-17 2013-03-28 애보트 리서치 비.브이. Anti-nerve growth factor(ngf) antibody compositions
BR122019024201B1 (en) 2010-05-20 2021-08-03 Array Biopharma Inc MACROCYCLIC COMPOUND AS TRK KINASE INHIBITORS, ITS USE, AND PHARMACEUTICAL COMPOSITION
JOP20190250A1 (en) * 2010-07-14 2017-06-16 Regeneron Pharma Stabilized formulations containing anti-ngf antibodies
AU2015258217A1 (en) * 2010-08-19 2015-12-03 Zoetis Belgium S.A. Anti-NGF antibodies and their use
ES2665954T3 (en) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9783601B2 (en) * 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
CN102198272B (en) * 2011-05-27 2013-01-02 北京中科拜克生物技术有限公司 Medicinal composition for promoting fracture union and repairing injured nerves
RS56876B1 (en) * 2011-08-11 2018-04-30 Astellas Pharma Inc Novel anti-human ngf antibody
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
HRP20191690T1 (en) 2012-04-27 2019-12-27 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
JO3820B1 (en) * 2012-05-03 2021-01-31 Regeneron Pharma Human antibodies to FEL D1 and methods for their use
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
RU2666990C2 (en) 2012-08-13 2018-09-13 Дженентек, Инк. Antibodies to jagged and methods of their use
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
JP6135161B2 (en) * 2013-02-08 2017-05-31 アステラス製薬株式会社 Novel anti-human NGF antibody
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP3036543B1 (en) 2013-08-23 2019-06-19 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
AU2015209140B2 (en) * 2014-01-24 2020-01-02 William R. Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
TWI754319B (en) 2014-03-19 2022-02-01 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
TWI746426B (en) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
ES2809455T3 (en) 2014-11-17 2021-03-04 Regeneron Pharma Methods for tumor treatment using CD3xCD20 bispecific antibody
IL282614B2 (en) 2015-02-06 2024-02-01 Cell Idx Inc Antigen-coupled immunoreagents
CN104774265B (en) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 The neutralizing monoclonal antibody 11F1 and its hybridoma cell strain of anti human nerve growth factor
CN104777311B (en) * 2015-02-12 2016-08-17 北京华安科创生物技术有限公司 The monoclonal antibody of anti human nerve somatomedin hNGF and the immue quantitative detection reagent box of hNGF
CN104910274B (en) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 The neutralizing monoclonal antibody 12C11 and its hybridoma cell strain of anti human nerve growth factor
WO2016190263A1 (en) 2015-05-22 2016-12-01 アステラス製薬株式会社 NOVEL ANTI-HUMAN NGF ANTIBODY Fab FRAGMENT
CA2994638A1 (en) * 2015-08-13 2017-02-16 Merck Patent Gmbh Combination composition comprising fgf-18 compound
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
UA125025C2 (en) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. Methods of treating pediatric cancers
UA125026C2 (en) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. Liquid formulations of (s)-n-(5-(r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
CN107286233B (en) * 2016-04-13 2020-11-06 舒泰神（北京）生物制药股份有限公司 low pain nerve growth factor mutant
MX392604B (en) 2016-05-18 2025-03-24 Array Biopharma Inc Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide
US12123874B2 (en) * 2016-07-18 2024-10-22 Cell Idx, Inc. Reagent compounds, compositions, kits, and methods for amplified assays
JOP20190092A1 (en) 2016-10-26 2019-04-25 Array Biopharma Inc PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
MA45890B2 (en) * 2016-11-29 2022-10-31 Regeneron Pharma Pharmaceutical composition for preventing opioid addiction
PL3558347T3 (en) 2016-12-22 2026-04-20 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
CN109929035B (en) * 2017-12-15 2022-06-28 安源医药科技（上海）有限公司 Anti-human NGF antibody and preparation method and use thereof
CN108059676B (en) * 2017-12-28 2020-07-31 未名生物医药有限公司 Anti-human nerve growth factor scFv antibody and preparation method thereof
BR112020017701A2 (en) 2018-03-12 2020-12-29 Zoetis Services Llc ANTI-NGF ANTIBODIES AND METHODS OF THE SAME
WO2019200326A1 (en) 2018-04-13 2019-10-17 Rarecyte, Inc. Kits for labeling of biomarkers and methods of using the same
CN108623687A (en) 2018-04-17 2018-10-09 中山康方生物医药有限公司 Monoclonal antibody of nerve growth factor and coding gene and application thereof
JPWO2019221097A1 (en) 2018-05-15 2021-05-27 アステラス製薬株式会社 A pharmaceutical composition for suppressing atrial fibrillation containing an anti-human NGF antibody or an antigen-binding fragment thereof as an active ingredient.
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
KR20210043624A (en) * 2018-08-10 2021-04-21 리제너론 파아마슈티컬스, 인크. Pharmaceutical composition for safe and effective treatment of knee and/or hip joint pain
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
JP2020117502A (en) 2019-01-28 2020-08-06 ファイザー・インク Methods of treating signs and symptoms of osteoarthritis
EP3927430A1 (en) 2019-02-18 2021-12-29 Pfizer Inc. Method of treatment of chronic low back pain
CA3135181A1 (en) * 2019-04-05 2020-10-08 B-Portal Biologics, Inc. Fusion constructs and uses thereof
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
CN113924315B (en) * 2019-06-10 2022-06-28 山东博安生物技术股份有限公司 anti-beta-NGF nano antibody and application thereof
EP4084818A2 (en) * 2019-12-31 2022-11-09 Peptinov Pharmaceutical composition for the prevention or treatment of post-surgical pain
CN117050175B (en) * 2020-04-17 2024-07-16 珠海泰诺麦博制药股份有限公司 Antibodies against human nerve growth factor
CN117186219B (en) * 2020-04-17 2024-07-12 珠海泰诺麦博制药股份有限公司 Anti-human nerve growth factor antibody
WO2021238886A1 (en) * 2020-05-27 2021-12-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
AU2020204105B2 (en) * 2020-06-19 2023-06-08 Dartsbio Pharmaceuticals Ltd. Anti-human ngf antibodies and methods using same
US11655292B2 (en) 2020-06-23 2023-05-23 Ampsource Biopharma Shanghai Inc. Anti-human NGF antibodies and methods using same
CN116003590A (en) 2020-08-06 2023-04-25 熙源安健医药（上海）有限公司 anti-NGF antibodies and antigen binding fragments thereof, methods of making and uses thereof
IL301548A (en) 2020-09-28 2023-05-01 Medimmune Ltd Compounds and methods for treating pain
CN114470189B (en) * 2020-11-12 2024-01-16 达石药业(广东)有限公司 Application of NGF antibodies in CIPN pain
WO2022133094A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Fap binding molecules and uses thereof
WO2022195504A1 (en) 2021-03-19 2022-09-22 Pfizer Inc. Method of treating osteoarthritis pain with an anti ngf antibody
CN115725684A (en) * 2021-08-28 2023-03-03 达石药业(广东)有限公司 Method for detecting cell proliferation inhibition activity of Anti-NGF drug
WO2023092052A1 (en) 2021-11-19 2023-05-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
MX2024007088A (en) 2021-12-16 2024-08-22 Intervet Int Bv CANINIZED ANTIBODIES AGAINST HUMAN NGF.
CN114397453B (en) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 Detection kit for novel coronavirus mutant strain and application thereof
US20240002491A1 (en) 2022-04-27 2024-01-04 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US514294A (en) * 1894-02-06 Governor
US5147294A (en) 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
RU94016525A (en) * 1991-07-10 1996-06-10 Ридженерон Фармасьютикалз Methods for treating motor neurone diseases
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
IT1306704B1 (en) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R MONOCLONAL ANTIBODIES AND ITS SYNTHETIC OR BIOTECHNOLOGICAL DERIVATIVES ENABLE TO ACT AS ANTAGONIST MOLECULES FOR NGF.
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (en) 2000-04-13 2001-10-19 Warner Lambert Co Use of a nerve growth factor antagonist for the manufacture of a medicament for the prevention or treatment of chronic visceral pain
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AUPR256601A0 (en) * 2001-01-17 2001-02-08 Silverbrook Research Pty. Ltd. An apparatus (AP29)
KR20100132559A (en) 2001-05-30 2010-12-17 제넨테크, 인크. Anti-ENG antibodies useful for the treatment of various diseases
EP1542724A4 (en) * 2002-08-19 2005-10-19 Abgenix Inc Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
WO2004032870A2 (en) 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK1575517T3 (en) * 2002-12-24 2012-05-14 Rinat Neuroscience Corp ANTI-NGF ANTIBODIES AND PROCEDURES FOR USING THE SAME
KR20050111598A (en) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
UA97086C2 (en) 2003-07-15 2012-01-10 Емджен, Інк. ALLOCATED HUMAN ANTIBODY THAT SPECIFICALLY RELATIVES TO THE NERVOUS TISSUE GROWTH FACTOR (NGF)
EP1706425A2 (en) * 2003-12-05 2006-10-04 John R. Schreiber Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse®
ITRM20030601A1 (en) 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
KR101637908B1 (en) 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
JP5096167B2 (en) * 2005-01-24 2012-12-12 メドイミューン リミテッド Specific binding member for NGF
ITRM20050290A1 (en) 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
SI1937721T1 (en) * 2005-08-25 2010-11-30 Lilly Co Eli Anti-il-23 antibodies
US9789161B2 (en) 2006-04-28 2017-10-17 Warsaw Orthopedic, Inc. Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin
ATE537190T1 (en) 2006-06-02 2011-12-15 Regeneron Pharma HIGH AFFINE ANTIBODIES AGAINST THE HUMAN IL-6 RECEPTOR
PL2187964T3 (en) 2007-08-10 2015-03-31 Regeneron Pharma High affinity human antibodies to human nerve growth factor
ES2514319T3 (en) 2009-05-04 2014-10-28 Abbvie Research B.V. Antibodies against nerve growth factor (NGF) with improved in vivo stability

Also Published As

Publication number Publication date
PT2187964E (en) 2015-01-14
MA31695B1 (en) 2010-09-01
DOP2010000054A (en) 2010-03-15
KR20150125735A (en) 2015-11-09
US8148107B2 (en) 2012-04-03
HRP20141025T1 (en) 2015-01-02
CN101827609B (en) 2014-03-12
JP2010535509A (en) 2010-11-25
DK2187964T3 (en) 2015-01-12
HK1144379A1 (en) 2011-02-18
AU2008287037B2 (en) 2013-10-10
EP2187964A1 (en) 2010-05-26
ME00977B (en) 2012-06-20
KR101709495B1 (en) 2017-02-23
BRPI0815370B8 (en) 2021-05-25
EP2187964B1 (en) 2014-10-08
RU2010108525A (en) 2011-09-20
NI201000021A (en) 2010-07-27
CY1116072T1 (en) 2017-02-08
ME02239B (en) 2015-04-30
CO6261383A2 (en) 2011-03-22
NZ583200A (en) 2012-03-30
RS53661B1 (en) 2015-04-30
RU2473564C2 (en) 2013-01-27
JP5632744B2 (en) 2014-11-26
WO2009023540A1 (en) 2009-02-19
MX2010001395A (en) 2010-03-10
BRPI0815370B1 (en) 2020-10-20
TN2010000059A1 (en) 2011-09-26
SI2187964T1 (en) 2015-01-30
US20120164688A1 (en) 2012-06-28
MY161564A (en) 2017-04-28
CA2695997C (en) 2016-11-22
PL2187964T3 (en) 2015-03-31
KR20100058537A (en) 2010-06-03
CR11298A (en) 2010-03-23
US7988967B2 (en) 2011-08-02
US8613927B2 (en) 2013-12-24
ZA201000725B (en) 2011-06-29
MY153781A (en) 2015-03-13
EP2572729A3 (en) 2013-06-05
ES2517872T3 (en) 2014-11-04
IL203558A (en) 2014-03-31
US20110256587A1 (en) 2011-10-20
US20090041717A1 (en) 2009-02-12
BRPI0815370A2 (en) 2015-02-10
AU2008287037A1 (en) 2009-02-19
CA2695997A1 (en) 2009-02-19
EP2572729A2 (en) 2013-03-27
CN101827609A (en) 2010-09-08
KR101709488B1 (en) 2017-02-24

Similar Documents

Publication Publication Date Title
NI201000021A (en) HUMAN ANTIBODIES OF HIGH AFFINITY GROWTH FACTOR OF HUMAN NERVE.
CY1119290T1 (en) CLAUDIN-18 MONOCLONE ANTIBODIES FOR CANCER TREATMENT
AR106570A1 (en) ANTI-PSMA ANTIBODIES, BIO-SPECIFIC ANTIGEN MOLECULES THAT JOIN PSMA AND CD3, AND USES OF THESE
CY1122490T1 (en) ANTIBODIES TO HUMAN CD38
BR112021023295A2 (en) Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf-alpha
GT201200271A (en) PROTEINS THAT JOIN TNF-A
BR112016030686A2 (en) humanized anti tau antibodies
PE20191661A1 (en) INHIBITORS OF TGF BETA1 ISOFORM-SPECIFIC CONTEXT-PERMISIVES AND USE OF THE SAME
BR112012022102A2 (en) a-beta binding polypeptides.
BR112021008060A2 (en) Polypeptide, anti-ctla4 antibody or antibody fragment, immunoconjugate, pharmaceutical composition, single dose of pharmaceutical composition, method of treating cancer, and, kit for diagnosis or treatment
ECSP14001260A (en) BI-SPECIFIC IMMUNOLIGANTS TARGETED AGAINST TNF AND IL-17 CROSS REFERENCE TO RELATED REQUESTS
BR112012032991A2 (en) mouse expressing a hybrid light chain immunoglobulin.
UY34387A (en) COMPOSITIONS FOR THE TREATMENT OF Rheumatoid ARTHRITIS AND METHODS FOR USE.
PE20120549A1 (en) BISPECIFIC ANTIGEN BINDING PROTEINS
AR096015A1 (en) CONJUGATES OF DRUGS WITH ANTIBODIES
EA201390611A1 (en) MULTISPECIFIC ANTIGENSORATING PROTEINS DIRECTED AT HGF
BR112012023010A2 (en) "antibody or antigen binding fragment thereof which specifically binds to cd37, immunoconjugate comprising them, use of said antibody, fragment and immunoconjugate, composition comprising them, kit, isolated cell, as well as in vitro method for inhibiting growth" of a cell expressing cd37 "
PE20141659A1 (en) ANTI-VGF SINGULAR VARIABLE DOMAINS FUSED WITH FC DOMAINS
PE20141162A1 (en) ANTI-IL-23 ANTIBODIES
CO6270341A2 (en) LINKED MOLECULES THAT INCLUDE AN PORTION OF ANTIGEN UNION THAT JOINS THE NEO-EPITOPE C3B MODULATING THE COMPLEMENT COMPONENT
EA200970210A1 (en) PRLR-SPECIFIC ANTIBODY AND ITS APPLICATIONS
BR112018073945A2 (en) Methods for treating refractory generalized myasthenia gravis
MX366890B (en) Anti-gcc antibody molecules and related compositions and methods.
DOP2014000083A (en) IMMUNO LINKERS AGAINST TNF
CY1116313T1 (en) ANTIBODIES AGAINST IL-25